Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71335-2022

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-2022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Donepezil Figure 1)

A line graph showing ADAS-cog change from baseline (mean ± SE) over 24 weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. Results indicate clinical improvement with Donepezil treatments and clinical decline with placebo over time, with measurements at intervals including baseline, 6, 12, 18, and 24 weeks.*

FDA Label Image

Fig-10 (Donepezil Figure 10)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day versus placebo, plotting ADCS-ADL change from baseline on the x-axis against cumulative patient percentage on the y-axis, showing a distribution shift between the drug and placebo treatments.*

FDA Label Image

Fig-11 (Donepezil Figure 11)

A line graph depicting the change from baseline in SIB (Severe Impairment Battery) mean scores over 24 weeks of drug treatment for Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The graph shows clinical improvement and decline with error bars representing the standard error for each time point.*

FDA Label Image

Fig-12 (Donepezil Figure 12)

A cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride at doses of 23 mg/day and 10 mg/day. The x-axis represents SIB change from baseline, and the y-axis represents the cumulative percentage of patients. Two curves are shown, one for each dose level.*

FDA Label Image

Fig-13 (Donepezil Figure 13)

A bar graph comparing the percentage of patients at various CIBIC-plus ratings for Donepezil Hydrochloride 23 mg/day and 10 mg/day. The x-axis shows CIBIC-plus ratings from Markedly Improved to Markedly Worse, and the y-axis indicates the percentage of patients. Two data sets are represented: black bars for 23 mg/day and white bars for 10 mg/day doses.*

FDA Label Image

Fig-2 (Donepezil Figure 2)

A cumulative percentage graph comparing patient response to Donepezil Hydrochloride 5 mg and 10 mg tablets versus placebo based on changes in ADAS-cog scores from baseline. The x-axis shows change from baseline ranging from -15 to 15, while the y-axis shows cumulative percentage of patients from 0% to 100%. The graph includes markers for 7 points, 4 points, and no change, with a table summarizing treatment group percentages achieving various ADAS-cog score changes.*

FDA Label Image

Fig-3 (Donepezil Figure 3)

A bar graph comparing the percentage of patients rated by CIBIC-plus categories for three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The categories include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse.*

FDA Label Image

Fig-4 (Donepezil Figure 4)

A line graph showing the ADAS-cog change from baseline (mean ±SE) over weeks of drug treatment up to 15 weeks. It compares Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, illustrating clinical improvement and decline relative to baseline with Donepezil groups showing greater improvement versus placebo.*

FDA Label Image

Fig-5 (Donepezil Figure 5)

A cumulative percentage graph showing patients' changes from baseline measured by ADAS-cog scores. It compares Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, illustrating percentage improvements and no change across different score thresholds. A table details treatment group percentages at score changes of -7, -4, and 0.*

FDA Label Image

Fig-6 (Donepezil Figure 6)

A bar graph showing the percentage of patients by CIBIC-plus rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Categories include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with percentages on the vertical axis.*

FDA Label Image

Fig-7 (Donepezil Figure 7)

A line graph depicting SIB (Severe Impairment Battery) change from baseline (mean ± SE) over 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day to placebo, showing clinical improvement or decline on the vertical axis, with the Donepezil group improving and placebo declining over time.*

FDA Label Image

Fig-8 (Donepezil Figure 8)

A cumulative percentage line graph comparing Donepezil Hydrochloride 10 mg/day and placebo groups. The X-axis represents SIB change from baseline ranging from 30 to -75, while the Y-axis shows cumulative percentage of patients from 0 to 100%. The graph uses filled circles for Donepezil Hydrochloride 10 mg/day and open squares for placebo, illustrating patient response distribution.*

FDA Label Image

Fig-9 (Donepezil Figure 9)

A line graph showing ADCS-ADL change from baseline mean (± SE) over 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day and placebo groups, indicating clinical improvement or decline from baseline over time.*

FDA Label Image

Str (Donepezil Str)

Chemical structure diagram of Donepezil Hydrochloride showing the arrangement of its molecular components including aromatic rings, piperidine ring, and hydrochloride ion.*

FDA Label Image

Label (Lbl713352022)

Donepezil 5 mg tablet label by Bryant Ranch Prepack. The label indicates the product is a white round tablet, packaged in a quantity of 90. It includes a reference to Aricept 5 mg tablets by Macleods Pharmaceutical Ltd. Storage instructions specify room temperature 20°-25°C (68°-77°F), and it includes safety advice to keep drugs out of reach of children. A barcode and NDC 71335-20221 are present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.